<DOC>
	<DOCNO>NCT01400451</DOCNO>
	<brief_summary>Treatment subject metastatic melanoma express activate mutant form BRAF oncogene ( V600E ) combination specific BRAF inhibitor , Vemurafenib , Cytotoxic T Lymphocyte Antigen 4 ( CTLA-4 ) inhibitor mAb Ipilimumab safe feasible show preliminary evidence anti-tumor efficacy survival comparison historical result follow treatment either agent alone .</brief_summary>
	<brief_title>Ph I Ipilimumab Vemurafenib Combo Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 ( BRAF )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Metastatic melanoma activate V600 BRAF mutation Measurable Tumor Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 01 Autoimmune disease Active Brain Metastasis ( must stable radiation least one month ) Prior therapy immune stimulate agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>